UK Approves Eli Lilly's Orforglipron, First Obesity Pill Authorized in Europe

The United Kingdom has granted marketing authorization for orforglipron, Eli Lilly's oral medication for obesity and type 2 diabetes. This marks the first approval of such a pill in Europe, positioning the UK as a pioneer in offering this new class of treatment.

“

It is a medicine subject to medical prescription.

The British Medicines and Healthcare products Regulatory Agency (MHRA) confirmed the decision, classifying orforglipron as a prescription-only medicine. The agency stated it will maintain close surveillance of the drug's safety and efficacy. This oral formulation, already approved in the United States under the brand name Foundayo, represents a significant step in the race to develop more user-friendly obesity treatments compared to existing injectable options.

Orforglipron is designed to be taken once daily and offers flexibility in timing, without specific requirements for food or water intake. This convenience factor is a key differentiator in the growing market for obesity treatments. However, despite its UK approval, the pill is not currently available through the National Health Service (NHS), the UK's public healthcare system. It will need to undergo a separate validation process for NHS inclusion.

“

it will maintain close surveillance of the safety and efficacy of this molecule.

This development occurs amidst intense competition among pharmaceutical companies. Eli Lilly's oral treatment faces competition from similar formulations, including Novo Nordisk's Wegovy, which is already authorized in the UK, US, and EU. Additionally, other companies like AstraZeneca are exploring oral anti-obesity medications, with preliminary studies suggesting comparable weight loss results to existing oral treatments, though further trials are needed.

“

Although this tablet is approved for use in the United Kingdom, it is not currently available via the NHS.